Zurich-Schlieren, Switzerland, March 20, 2020.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies, today published its audited Financial Results for 2019 and the company’s 2019 Annual Report.

Zurich-Schlieren, Switzerland, February 24, 2020.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies, today announced that senior management will present at two upcoming healthcare investor conferences.

Sandip Kapadia, Michael Vasconcelles and Vito J. Palombella nominated for election to the Board of Directors of Molecular Partners at the upcoming Annual General Meeting Nominees bring extensive expertise in the fields of oncology drug discovery, translational science, clinical development,

Zurich-Schlieren, Switzerland, January 6, 2020.   Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics to treat serious diseases, today announced that it will present at the 38 th  Annual J.P. Morgan Healthcare Conference on Thursday, January

Research & Development: Abicipar in Neovascular Wet Age-Related Macular Degeneration: Two-year results from CEDAR and SEQUOIA presented at AAO in October 2019 demonstrate that vision gains observed after one year with both, every 8-week and every 12-week dosing were maintained in second year FDA

Zurich-Schlieren, Switzerland, January 06, 2021.   Molecular Partners AG  (SIX: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will present at or

Zurich-Schlieren, Switzerland, December 27, 2019.   Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics to treat serious diseases, announces the receipt of Orphan Drug Designation by the US Food and Drug Administration (FDA) for its novel

Nicolas Leupin, CMO, highlights progress in the development of all three DARPin® product candidates in clinical trials: MP0250 in phase 2 clinical development, MP0274 in phase 1, and MP0310 in co-development with Recent data presented for MP0250 in relapsed/refractory multiple myeloma at ASH

Poster highlights Overall Response Rate (ORR) of 45% in heavily pretreated MM population Strong evidence of durable and deepening responses with ongoing treatment in excess of 9 months in multiple patients, including one patient who achieved a Complete Response (CR) Mechanism of action targeting

Research & Development: MP0310 (FAP x 4-1BB): First patient dosed in phase 1 trial for this tumor-localized immune-modulator, representing a key milestone as the first novel therapeutic design of an immuno-oncology DARPin® candidate in clincial development (in co-development with Amgen) MP0250